Project Grant F32DA062467
Award Date
4/1/25
Completion Date
3/31/28
Dollars Obligated
$74K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Ithaca, NY, USA
Similar Awards
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), is providing $627,945 to Cornell University to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The research aims to: 1) measure the spiking activity of different interneuron subtypes in response to psilocybin administration, 2) determine if serotonin receptors expressed in the interneurons...
The National Institute of Mental Health (NIMH) awarded a 5-year, $679,118 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the University of California Santa Cruz (UCSC) to investigate the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The key objectives are to:
Determine the acute and enduring effects of psilocybin on synaptic plasticity, cortical functional networks,...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $495,024 to The Trustees of the University of Pennsylvania to conduct research on the effects of psilocybin on neurocognitive function and motivation in individuals with opioid use disorder. The 2-year project aims to examine psilocybin's impact on brain activity, cognition, and behavior across three key domains: motivation, inhibitory control,...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $708,511 Project Grant under the Alcohol Research Programs (CFDA 93.273) to New York University School of Medicine to conduct a mechanistic trial investigating the effects of psilocybin on neural activity, drinking outcomes, and self-report measures related to negative emotionality, craving, and executive function in patients with alcohol use disorder (AUD). The 5-year study will randomly assign 90 AUD patients in...
This federal Project Grant award in the amount of $131,990 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will investigate the effects of psychedelic 5-HT2A agonist drugs on reversing aberrant reward-seeking behavior in an animal model of early-life adversity. The research, to be conducted by the University of California, Irvine, aims to replicate and extend previous findings showing that a single dose of the psychedelic...
This $509,279 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports research into the role of 5-HT2A receptor signaling in treating stimulant use disorder. The principal investigator and prime awardee, The Medical College of Wisconsin, Inc., will conduct studies examining how 5-HT2A receptor agonists, including psychedelic drugs, can suppress the reinforcing effects of methamphetamine, promote neuroplasticity, and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,603,784 to Brigham & Women's Hospital to study the effects of psilocybin on a neuroimmune circuit that controls stress behaviors relevant to substance use disorders. The project aims to define how psilocybin impacts peripheral immune cells, understand how these immune cells regulate astrocytes in the nucleus accumbens, and evaluate the...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $237,000 to the University of California, San Diego (UC San Diego) to study the efficacy of psychedelic agents in reversing depression-relevant behaviors and associated EEG biomarkers in mice. The 2-year project aims to assess whether chronic corticosterone treatment, short-active winter-like photoperiod, and the acetylcholinesterase inhibitor...
The U.S. National Institute on Drug Abuse (NIDA) awarded a $3,244,725 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University (NYU) School of Medicine. The award will support a clinical trial evaluating the efficacy of psilocybin as an adjunctive treatment for opioid use disorder (OUD) in methadone-maintained patients who continue to use illicit opioids. The study will recruit 240 participants from opioid treatment programs in New York and...
The National Institute of Biomedical Imaging and Bioengineering awarded Interval Therapeutics LLC a $306,556 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to develop bioresorbable microdevices that deliver intermittent sub-perceptual doses of 5HT2A agonists, such as psilocybin, to mitigate depression associated with opioid use disorder. The devices utilize a microfluidic "fuse" made from biodegradable polymers to...